Most individuals diagnosed with<unk>  in the United States (88%) are of Mexican descent and reside in Southwest region of the United States (New Mexico, Arizona, far Western Texas). Other groups with higher incidence rates of the disorder include First Nation Peoples in Canada, Punjabis, South Asians, Sudanese, Native Americans, and Egyptians. In Egyptians, for example,<unk>  is second most common cause of renal amyloidosis, accounting for nearly 31% of all cases.<unk>  <unk>  is generally diagnosed in individuals between the ages 40 and 90, with a mean age of 67 years old. The disorder commonly presents with renal disease that in general is advanced or at an end stage. Associated signs and symptoms of their renal disease may include fatigue, dehydration, blood in urine, and/or other evidence for the presence of the nephrotic syndrome or renal failure. Further studies may find that these individuals have histological or other evidence of<unk>  amyloid deposition in the liver, lung, spleen, kidney, and/or adrenal glands but nonetheless they rarely show any symptoms or signs attributable to dysfunction in these organs. Unlike many other forms of systemic amyloidosis,<unk>  deposition has not been reported to be deposited in the myocardium or brain of affected individuals. Thus,<unk> , while classified as a form of systemic amyloidosis, almost exclusively manifests clinically as renal amyloidosis. No familial link has been found in the disorder although there have been several cases described among siblings.
LECT2 amyloidosis
AA amyloidosis
AL amyloidosis
Secondary systemic amyloidosis
Anti-AQP4 disease
Sarcoglycanopathy
Hyaluronidase deficiency
Monoclonal gammopathy